alendronate has been researched along with ranitidine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Freeman, A; Gertz, BJ; Holland, SD; Kline, WF; Lasseter, KC; Matuszewski, BK; Mucklow, JC; Porras, AG; Quan, H | 1 |
| Castelino, RL; Jose, MD; Khanal, A; Peterson, GM | 1 |
1 review(s) available for alendronate and ranitidine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for alendronate and ranitidine
| Article | Year |
|---|---|
Studies of the oral bioavailability of alendronate.
Topics: Achlorhydria; Administration, Oral; Adult; Aged; Alendronate; Analysis of Variance; Beverages; Biological Availability; Calcium; Cross-Over Studies; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Food; Gastric Mucosa; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Ranitidine | 1995 |
5 other study(ies) available for alendronate and ranitidine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Renal drug dosing recommendations: evaluation of product information for brands of the same drug.
Topics: Administration, Oral; Alendronate; Cardiovascular Agents; Central Nervous System Agents; Contraindications; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Labeling; Drugs, Generic; Glomerular Filtration Rate; Gout Suppressants; Humans; Hypoglycemic Agents; Kidney; Kidney Diseases; Kidney Function Tests; Narcotics; Pharmaceutical Preparations; Psychotropic Drugs; Ranitidine; Renal Insufficiency, Chronic | 2014 |